Scammers, Spammers, and Slammers

[Phil(Hot Rod Chevy)]

Print conversation Print Open conversation in new window New window
Emerging Growth 0pportunity
Inbox
Add star
Jon De Egiarte
<[e-mail]> Sat, Dec 12, 2009 at 6:43 AM
To: [e-mail], [e-mail], [e-mail], [e-mail], [e-mail], [e-mail], [e-mail], [e-mail], [e-mail], [e-mail], [e-mail]
Reply | Reply to all | Forward | Print | Delete | Show original
A nearly 200% boost expected within DAYS

Symbol - FROI
Current - .55
Short Target - 1.35+
Long Target - 3.80+
Rating - 10 of 10

Our goal is simple. Recommend the top micro-caps, penny stocks, and momentum trades that are ready to explode. And by the time other traders have caught on, you?ll have already pocketed 50 %, 100 %,200% or more ! Here's today's hot pick. Fero Industries, Inc. (OTCBB: FROI - News) recently disclosed its growth strategy. FROI?s first acquisition target is Pyro Pharmaceuticals, Inc., a boutique developmental stage pharmaceutical company located in Irvine, CA. Pyro?s focus is on developing a new class of antibiotics to fight drug resistant bacteria, such as life-threathening MRSA.

Fero?s aggressive synergistic growth through acquisition strategy for 2010 has already begun with initial negotiations, contact, and current due diligence taking place on two private and five public companies. Fero intends to parlay the Pyro acquisition by blending Pyro?s world class management team and future acquisitions to grow the companies both horizontally and vertically. Don?t miss out on this super gem in the making. The stock is currently trading at the $0.60 level and could be poised to explode as future acquisition targets are announced. With world class management and synergistic acquisitions in the pipeline, Fero (FROI.OB) could be just what the doctor ordered for your portfolio in 2010!

Now that the recovery is under way, it seems Wall Street is more interested in the little guys?one-drug biotech stocks that could rally double-digits on a single breakthrough, or up-and-comers that are in a prime position to be bought out by a big pharma powerhouse and see shares soar on a takeover bid. These companies are on the cutting-edge of innovation, researching and developing treatments for everything from Anthrax and Swine Flu to MRSA and cancer?and Wall Street is watching them closely.

Diamond Equities